Baseline characteristics of the participants in the US cohort (GeneBank) and the European cohort (LipidCardio) (n = 4833)
| Characteristics . | All participants (n = 4833) . |
|---|---|
| Age (years) | 64.9 (56.1–73.5) |
| Male sex (%) | 65.4 |
| Smoking (%) | 13.4 |
| Hypertension (%) | 46.0 |
| Diabetes (%) | 30.9 |
| CAD (%) | 76.2 |
| MACE at 3 years, (%) | 14.7 |
| HDL (mg/dL) | 35.7 (29.3–44.3) |
| LDL (mg/dL) | 95.0 (76.0–117.0) |
| TG (mg/dL) | 119.0 (87.0–166.0) |
| hsCRP (mg/L) | 2.34 (1.00–5.73) |
| eGFR (mL/min/1.73 m²) | 88.76 (71.97–99.13) |
| Baseline medications (%) | |
| Aspirin (%) | 70.7 |
| ACE inhibitors (%) | 53.6 |
| Beta blocker (%) | 62.3 |
| Statin (%) | 60.1 |
| Characteristics . | All participants (n = 4833) . |
|---|---|
| Age (years) | 64.9 (56.1–73.5) |
| Male sex (%) | 65.4 |
| Smoking (%) | 13.4 |
| Hypertension (%) | 46.0 |
| Diabetes (%) | 30.9 |
| CAD (%) | 76.2 |
| MACE at 3 years, (%) | 14.7 |
| HDL (mg/dL) | 35.7 (29.3–44.3) |
| LDL (mg/dL) | 95.0 (76.0–117.0) |
| TG (mg/dL) | 119.0 (87.0–166.0) |
| hsCRP (mg/L) | 2.34 (1.00–5.73) |
| eGFR (mL/min/1.73 m²) | 88.76 (71.97–99.13) |
| Baseline medications (%) | |
| Aspirin (%) | 70.7 |
| ACE inhibitors (%) | 53.6 |
| Beta blocker (%) | 62.3 |
| Statin (%) | 60.1 |
The cohort was made by merging individuals from the GeneBank [US cohort (n = 4000)] and LipidCardio [European cohort (n = 833)], which consists of sequential stable subjects without evidence of acute coronary syndrome (cardiac troponin I <0.03 ng/mL) who underwent elective diagnostic coronary angiography (cardiac catheterization or coronary computed tomography) for evaluation of coronary artery disease (CAD). MACE was defined as death, nonfatal myocardial infarction (MI), or nonfatal cerebrovascular accident (stroke) following enrollment.
Continuous data are presented as median (interquartile range), categorical variables are presented as %; ACE angiotensin-converting enzyme, eGFR = estimated glomerular filtration rate. HDL high-density lipoprotein, hsCRP high-sensitivity C-reactive protein, LDL low-density lipoprotein.
Baseline characteristics of the participants in the US cohort (GeneBank) and the European cohort (LipidCardio) (n = 4833)
| Characteristics . | All participants (n = 4833) . |
|---|---|
| Age (years) | 64.9 (56.1–73.5) |
| Male sex (%) | 65.4 |
| Smoking (%) | 13.4 |
| Hypertension (%) | 46.0 |
| Diabetes (%) | 30.9 |
| CAD (%) | 76.2 |
| MACE at 3 years, (%) | 14.7 |
| HDL (mg/dL) | 35.7 (29.3–44.3) |
| LDL (mg/dL) | 95.0 (76.0–117.0) |
| TG (mg/dL) | 119.0 (87.0–166.0) |
| hsCRP (mg/L) | 2.34 (1.00–5.73) |
| eGFR (mL/min/1.73 m²) | 88.76 (71.97–99.13) |
| Baseline medications (%) | |
| Aspirin (%) | 70.7 |
| ACE inhibitors (%) | 53.6 |
| Beta blocker (%) | 62.3 |
| Statin (%) | 60.1 |
| Characteristics . | All participants (n = 4833) . |
|---|---|
| Age (years) | 64.9 (56.1–73.5) |
| Male sex (%) | 65.4 |
| Smoking (%) | 13.4 |
| Hypertension (%) | 46.0 |
| Diabetes (%) | 30.9 |
| CAD (%) | 76.2 |
| MACE at 3 years, (%) | 14.7 |
| HDL (mg/dL) | 35.7 (29.3–44.3) |
| LDL (mg/dL) | 95.0 (76.0–117.0) |
| TG (mg/dL) | 119.0 (87.0–166.0) |
| hsCRP (mg/L) | 2.34 (1.00–5.73) |
| eGFR (mL/min/1.73 m²) | 88.76 (71.97–99.13) |
| Baseline medications (%) | |
| Aspirin (%) | 70.7 |
| ACE inhibitors (%) | 53.6 |
| Beta blocker (%) | 62.3 |
| Statin (%) | 60.1 |
The cohort was made by merging individuals from the GeneBank [US cohort (n = 4000)] and LipidCardio [European cohort (n = 833)], which consists of sequential stable subjects without evidence of acute coronary syndrome (cardiac troponin I <0.03 ng/mL) who underwent elective diagnostic coronary angiography (cardiac catheterization or coronary computed tomography) for evaluation of coronary artery disease (CAD). MACE was defined as death, nonfatal myocardial infarction (MI), or nonfatal cerebrovascular accident (stroke) following enrollment.
Continuous data are presented as median (interquartile range), categorical variables are presented as %; ACE angiotensin-converting enzyme, eGFR = estimated glomerular filtration rate. HDL high-density lipoprotein, hsCRP high-sensitivity C-reactive protein, LDL low-density lipoprotein.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
